The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 24 October 2006, www.theannals.com, DOI 10.1345/aph.1H399.
 The Annals of Pharmacotherapy: Vol. 40, No. 12, pp. 2211-2215. DOI 10.1345/aph.1H399
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seamon, M. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seamon, M. J

DRUG INFORMATION ROUNDS

The Legal Status of Medical Marijuana

Matthew J Seamon, PharmD

JD Candidate, Assistant Professor, Pharmacy Practice, College of Pharmacy, Nova Southeastern University, 3200 S. University Dr., Fort Lauderdale, FL 33328-2018, fax 954/262-3170, mseamon{at}nova.edu

Reprints: Dr. Seamon

OBJECTIVE: To review the legal status of medical marijuana in the US.

DATA SOURCES: Relevant publications were located using LexisNexis (1982-October 2006), WestLaw (1996-October 2006), BNA Health Law Reporter (1996-October 2006), MEDLINE (1996-October 2006), EMBASE (1980-October 2006), International Pharmaceutical Abstracts (1970-October 2006), and an Internet search targeting government sites using the key words medical marijuana.

STUDY SELECTION AND DATA EXTRACTION: Federal and state medical marijuana laws were examined. Relevant cannabinoid-based drug products were reviewed. Federal and State Supreme Court and Appeal level cases involving medical marijuana were evaluated.

DATA SYNTHESIS: Marijuana is regulated as a Schedule I controlled substance and its use is prohibited under federal law. Dronabinol and nabilone are synthetic cannabinoids approved by the Food and Drug Administration and Sativex is a cannabis-based extract being evaluated in Phase III trials. The federal government sponsors a single patient compassionate use Investigational New Drug Application program providing medical marijuana for a small number of patients. Eleven states permit marijuana use for medical purposes and one state provides a defense of medical necessity. Employers do not have to provide workplace accommodations for employees using medical marijuana and can terminate them at will. Healthcare providers have First Amendment constitutional protections that allow them to discuss marijuana with patients.

CONCLUSIONS: Until the Supreme Court rules directly on the constitutionality of state medical marijuana laws, a conflict remains. Marijuana use remains illegal under federal law and states assume their medical marijuana laws to be constitutional.

Key Words: cannabinoids, Controlled Substances Act, marijuana

Published Online, October 24, 2006. www.theannals.com, DOI 10.1345/aph.1H399


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. J. Seamon, J. A. Fass, M. Maniscalco-Feichtl, and N. A. Abu-Shraie
Medical marijuana and the developing role of the pharmacist
Am. J. Health Syst. Pharm., May 15, 2007; 64(10): 1037 - 1044.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.